HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE3TerminatedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Interventions
DRUG

HC-1119

oral once daily 80 mg

DRUG

Enzalutamide

oral once daily 160 mg

Trial Locations (58)

4020

Kepler Universitätsklinikum Linz, Linz

4215

Icon Cancer Care Gold Coast, Southport

5000

Odense Universitetshospital, Odense C

5037

Ashford Cancer Centre Research, Kurralta Park

6009

Affinity Clinical Research, Nedlands

9000

Aalborg Universitetshospital, Aalborg

14004

C.H. Regional Reina Sofia - PPDS, Córdoba

17604

Keystone Urology Specialists, Lancaster

19004

MidLantic Urology, Bala-Cynwyd

20036

Urologic Surgeons of Washington, Washington D.C.

27003

Hospital Lucus Augusti, Lugo

28041

Hospital Universitario 12 de Octubre, Madrid

29009

Hospital Regional Universitario de Malaga - Hospital Civil, Málaga

33521

Tampereen yliopistollinen sairaala, Tampere

37126

Azienda Ospedaliera Universitaria Integrata Di Verona, Verona

41013

Hospital Universitario Virgen del Rocio - PPDS, Seville

42103

UroGynZentrum Wall, Wuppertal

44130

Clinical Research Solutions PC, Middleburg Heights

46009

Fundacion Instituto Valenciano de Oncologia, Valencia

47130

First Urology PSC, 101 Hospital Boulevard, Jeffersonville

53127

Universitätsklinikum Bonn, Bonn

59037

CHRU Lille, Lille

60220

Seinäjoen Keskussairaala, Seinäjoki

69008

Centre Léon Berard, Lyon

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

72000

Centre Jean Bernard Clinique Victor Hugo, Le Mans

72076

Universitätsklinikum Tübingen, Tübingen

72622

Urologische Studienpraxis, Nürtingen

80211

Urology Center of Colorado, 2777 Mile High Stadium Circle, Denver

90220

Oulun Yliopistollinen Sairaala, Oulu

92151

Hopital Foch, Suresnes

94160

Hopital d'Instruction des Armées de Begin, Saint-Mandé

98503

Providence Regional Cancer System, Lacey

153040

Ivanovo Regional Oncology Dispensary, Ivanovo

197022

First St. Petersburg State Medical University n.a. I.P Pavlov, Saint Petersburg

197758

GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg

199178

Hospital Orkli LLC, Saint Petersburg

249036

Federal State Institution Medical Radiology Research Center, Obninsk

644013

Clinical Oncology Dispensary, Omsk

656045

Altay Regional Oncology Center, Barnaul

78258-4223

Urology San Antonio Stone Oak, 18915 Meisner Drive, San Antonio

L6H 3P1

Fe/Male Health Centre, Oakville

J1H5N4

CIUSSS de l'Estrie-CHUS, Sherbrooke

00290

Helsinki University Hospital Comprehensive Cancer Center - PPDS, Helsinki

Unknown

Azienda Ospedaliera S Maria Di Terni, Terni

6532 SZ

Canisius Wilhelmina Ziekenhuis, Nijmegen

5623 EJ

Catharina Hospital, Eindhoven

8601 ZK

Antonius Ziekenhuis, Sneek

2545 AA

Hagaziekenhuis, The Hague

60-848

Clinical Research Center Spolka z Ograniczona, Poznan

41-400

NZOZ Centrum Urologiczne Sp zoo, Mysłowice

20-250

Onko-Centrum Sp. z o.o., Lublin

08-110

Urologica Praktyka Lekarska Adam Marcheluk, Siedlce

02-781

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warsaw

DN33 2BA

Diana Princess of Wales Hospital, Grimsby

BT9 7AB

Belfast City Hospital, Belfast

SW3 6JJ

Royal Marsden Hospital - London, London

HA6 2RN

Mount Vernon Hospital, Northwood

All Listed Sponsors
lead

Hinova Pharmaceuticals USA, Inc.

INDUSTRY

NCT03850795 - HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter